Prandial insulin
Insulin lispro (prandial)
INS_LISPRO
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.42 (-0.91 to 0.20) | 0.16 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.42 (-1.55 to 0.98) | 0.32 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.64 (-1.26 to 0.29) | 0.34 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.65 (-1.36 to 0.29) | 0.35 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 3.40 (0.81 to 6.80) | 0.00 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 3.27 (-3.46 to 10.31) | 0.04 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.82 (-3.69 to 6.83) | 0.17 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.88 (-3.53 to 7.08) | 0.22 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.22 (0.20 to 7.12) | 0.29 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.62 (0.09 to 3.42) | 0.33 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 8.84 (3.53 to 22.74) | 0.11 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.89 (2.43 to 10.28) | 0.22 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.06 (1.49 to 6.20) | 0.22 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.73 (1.27 to 5.64) | 0.25 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.46 (0.92 to 6.38) | 0.24 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.25 (0.72 to 6.71) | 0.27 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 1.69 (-1.39 to 4.72) | 0.12 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 1.64 (-1.61 to 5.05) | 0.16 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 5.50 (0.65 to 10.30) | 0.27 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 3.90 (-2.76 to 10.37) | 0.21 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.41 (0.98 to 1.99) | 0.30 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.33 (0.93 to 1.91) | 0.28 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.85 (0.44 to 1.69) | 0.71 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.86 (0.44 to 1.78) | 0.66 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.18 (0.10 to 0.31) | 0.94 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.19 (0.10 to 0.37) | 0.89 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.18 (0.07 to 0.41) | 0.95 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.19 (0.07 to 0.50) | 0.93 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.55 (0.36 to 0.83) | 0.88 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.54 (0.34 to 0.87) | 0.86 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.42 (0.15 to 1.04) | 0.84 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.44 (0.16 to 1.12) | 0.78 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.40 (0.03 to 5.10) | 0.63 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.41 (0.03 to 4.53) | 0.56 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.69 (0.04 to 10.24) | 0.53 |
Trials
- SURPASS-6A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)2020 · 1,428 randomized · 52 weeks
- NCT02690883Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study2016 · 92 randomized · 24 weeks
- PREVAILPreserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)2014 · 103 randomized · 8 weeks
- NCT02229227Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study2014 · 814 randomized · 26 weeks
- NCT00960661A Randomized Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Who Were Previously Treated by Basal Insulin Glargine With Either Metformin or Metformin and Sulfonylurea2009 · 637 randomized · 30 weeks